BACKGROUND: It has been indicated that the sphingolipid sphingosine-1-phosphate (S1P) restrains the ability of dendritic cells to migrate to lymph nodes. Furthermore S1P has been demonstrated to inhibit cell growth in human keratinocytes. However, only little is known about the effect of S1P in hyperproliferative and inflammatory in vivo models. OBJECTIVE: In this study, locally acting S1P was explored in different experimental mouse models of psoriasis vulgaris. METHODS: S1P and FTY720 were tested in the imiquimod-induced psoriasis mouse model, the mouse tail assay and a pilot study of the severe combined immunodeficiency mice (SCID). RESULTS: In the imiquimod model the positive control diflorasone diacetate and S1P, but not FTY720 reduced the imiquimod-induced epidermal hyperproliferation of the ear skin. This effect was confirmed in the SCID model, where S1P treated skin from patients suffering from psoriasis showed a decrease in epidermal thickness compared to vehicle. In the imiquimod model, there was also significant inhibition of ear swelling and a moderate reduction of inflammatory cell influx and oedema formation in ear skin by S1P treatment. The inflammatory response on the back skin was, however, only reduced by diflorasone diacetate. In the mouse tail assay, the influence of S1P and FTY720 in stratum granulosum formation was tested compared to the positive control calcipotriol. Whereas topical administration of calcipotriol led to a low but significant increase of stratum granulosum, S1P and FTY720 lacked such an effect. CONCLUSION: Taken together, these results imply that topical administration of S1P might be a new option for the treatment of mild to moderate psoriasis lesions.
BACKGROUND: It has been indicated that the sphingolipidsphingosine-1-phosphate (S1P) restrains the ability of dendritic cells to migrate to lymph nodes. Furthermore S1P has been demonstrated to inhibit cell growth in human keratinocytes. However, only little is known about the effect of S1P in hyperproliferative and inflammatory in vivo models. OBJECTIVE: In this study, locally acting S1P was explored in different experimental mouse models of psoriasis vulgaris. METHODS:S1P and FTY720 were tested in the imiquimod-induced psoriasismouse model, the mouse tail assay and a pilot study of the severe combined immunodeficiencymice (SCID). RESULTS: In the imiquimod model the positive control diflorasone diacetate and S1P, but not FTY720 reduced the imiquimod-induced epidermal hyperproliferation of the ear skin. This effect was confirmed in the SCID model, where S1P treated skin from patients suffering from psoriasis showed a decrease in epidermal thickness compared to vehicle. In the imiquimod model, there was also significant inhibition of ear swelling and a moderate reduction of inflammatory cell influx and oedema formation in ear skin by S1P treatment. The inflammatory response on the back skin was, however, only reduced by diflorasone diacetate. In the mouse tail assay, the influence of S1P and FTY720 in stratum granulosum formation was tested compared to the positive control calcipotriol. Whereas topical administration of calcipotriol led to a low but significant increase of stratum granulosum, S1P and FTY720 lacked such an effect. CONCLUSION: Taken together, these results imply that topical administration of S1P might be a new option for the treatment of mild to moderate psoriasis lesions.
Authors: Sabine Vettorazzi; Constantin Bode; Lien Dejager; Lucien Frappart; Ekaterina Shelest; Carina Klaßen; Alpaslan Tasdogan; Holger M Reichardt; Claude Libert; Marion Schneider; Falk Weih; N Henriette Uhlenhaut; Jean-Pierre David; Markus Gräler; Anna Kleiman; Jan P Tuckermann Journal: Nat Commun Date: 2015-07-17 Impact factor: 14.919